Quantcast

Latest Cadence Pharmaceuticals Inc. Stories

2010-11-11 05:00:00

SAN DIEGO, Nov. 11, 2010 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that it has priced an underwritten public offering of 11,500,000 shares of its common stock at a price to the public of $8.00 per share. The net proceeds from the sale of the shares, after estimated underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $86.2 million. The offering is expected to close on or about November 16,...

2010-11-08 05:30:00

SAN DIEGO, Nov. 8, 2010 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that it is offering to sell $85 million worth of shares of its common stock in an underwritten public offering. Cadence expects to grant the underwriters of the offering an option to purchase additional shares of common stock to cover over-allotments, if any. Deutsche Bank Securities Inc. is acting as sole book-running manager for the offering. Leerink Swann LLC is acting as co-lead...

2010-11-05 06:30:00

SAN DIEGO, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the three and nine months ended September 30, 2010. On November 2, Cadence announced that the U.S. Food and Drug Administration (FDA) approved OFIRMEV(TM) (acetaminophen) injection for the management...

2010-11-02 15:30:00

SAN DIEGO, Nov. 2, 2010 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for OFIRMEV(TM) (acetaminophen) injection, the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States. OFIRMEV is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the...

2010-10-29 15:00:00

SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its third quarter ended September 30, 2010 financial results on Friday, November 5, 2010. Cadence management will host a conference call and live webcast to discuss the financial results on Friday,...

2010-09-07 18:00:00

SAN DIEGO, Sept. 7 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company will present a corporate overview at the following investment conferences: Morgan Stanley Global Healthcare -- Conference Date: Tuesday, September 14, 2010 Time:...

2010-08-05 15:00:00

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the three and six months ended June 30, 2010. Second quarter 2010 highlights included: On May 4, 2010, the Company's New Drug Application (NDA), for its investigational product candidate, OFIRMEV(TM)...

2010-07-29 15:00:00

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its second quarter ended June 30, 2010 financial results after the market closes on Thursday, August 5, 2010. Cadence management will host a conference call and live webcast to discuss the financial...

2010-07-27 15:00:00

SAN DIEGO, July 27 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company will present a corporate overview at the following investment conferences: --Wedbush Securities Life Sciences Best Ideas Management Access Conference Date: Tuesday, August 3, 2010...

2010-06-21 15:00:00

SAN DIEGO, June 21 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that it has signed an agreement providing Cadence with an exclusive option to acquire Incline Therapeutics, Inc., a privately held specialty pharmaceutical company. The company simultaneously announced that it has closed a...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related